Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7KPM

Crystal structure of hEphB1 bound with ADP

Summary for 7KPM
Entry DOI10.2210/pdb7kpm/pdb
DescriptorEphrin type-B receptor 1, ADENOSINE-5'-DIPHOSPHATE (3 entities in total)
Functional Keywordshephb1, adp, transferase
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight32250.66
Authors
Ahmed, M.,Wang, P.,Sadek, H. (deposition date: 2020-11-11, release date: 2021-03-10, Last modification date: 2024-10-23)
Primary citationAhmed, M.S.,Wang, P.,Nguyen, N.U.N.,Nakada, Y.,Menendez-Montes, I.,Ismail, M.,Bachoo, R.,Henkemeyer, M.,Sadek, H.A.,Kandil, E.S.
Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain.
Proc.Natl.Acad.Sci.USA, 118:-, 2021
Cited by
PubMed Abstract: Previous studies have demonstrated that the synaptic EphB1 receptor tyrosine kinase is a major mediator of neuropathic pain, suggesting that targeting the activity of this receptor might be a viable therapeutic option. Therefore, we set out to determine if any FDA-approved drugs can act as inhibitors of the EphB1 intracellular catalytic domain. An in silico screen was first used to identify a number of tetracycline antibiotics which demonstrated potential docking to the ATP-binding catalytic domain of EphB1. Kinase assays showed that demeclocycline, chlortetracycline, and minocycline inhibit EphB1 kinase activity at low micromolar concentrations. In addition, we cocrystallized chlortetracycline and EphB1 receptor, which confirmed its binding to the ATP-binding domain. Finally, in vivo administration of the three-tetracycline combination inhibited the phosphorylation of EphB1 in the brain, spinal cord, and dorsal root ganglion (DRG) and effectively blocked neuropathic pain in mice. These results indicate that demeclocycline, chlortetracycline, and minocycline can be repurposed for treatment of neuropathic pain and potentially for other indications that would benefit from inhibition of EphB1 receptor kinase activity.
PubMed: 33627480
DOI: 10.1073/pnas.2016265118
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.608 Å)
Structure validation

242842

数据于2025-10-08公开中

PDB statisticsPDBj update infoContact PDBjnumon